                         SEQUENCE LISTING

<110>  Deutsches Krebsforschungszentrum
 
<120>  Immune Enhancers

<130>  DK16240PC

<150>  EP21162054.7
<151>  2021-03-11

<160>  16    

<170>  PatentIn version 3.5

<210>  1
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  hD1 linear inhibitory peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  preferably is a D amino acid

<400>  1

Tyr Ala Ile Ser Tyr Arg Gly Lys Thr Thr Leu Leu Cys 
1               5                   10              


<210>  2
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  hL1 linear inhibitory peptide

<400>  2

Tyr Thr Leu Asn Phe Arg Phe Trp Ser Asp His Ile Ser Trp Tyr Ser 
1               5                   10                  15      


Cys 
    


<210>  3
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  hD2 linear inhibitory peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  preferably is a D amino acid

<400>  3

Tyr His Gln Trp Ser Tyr Arg Gly Ala Thr Tyr Arg Ser Cys 
1               5                   10                  


<210>  4
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  hD3 linear  inhibitory peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  preferably is a D amino acid

<400>  4

Tyr Asn Gly Pro Ser Tyr Tyr Arg Leu Arg Ser Trp Leu Ser Ser Cys 
1               5                   10                  15      


<210>  5
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  hD4 linear  inhibitory peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  preferably is a D amino acid

<400>  5

Tyr Trp Ile Thr His Ser Tyr Arg Gly Leu Ser Lys Ser Phe Cys 
1               5                   10                  15  


<210>  6
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  hD5 linear inhibitory peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  preferably is a D amino acid

<400>  6

Tyr Gln Thr Trp Ser Trp Arg Gly Arg Arg Tyr Ser Phe Cys 
1               5                   10                  


<210>  7
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  yL1 linear inhibitory peptide

<400>  7

Tyr Leu His Asp Ser Ala Phe Ser Phe Gly Trp Ser Leu Arg Leu Tyr 
1               5                   10                  15      


Cys 
    


<210>  8
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  yD1 linear inhibitory peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  preferably is a D amino acid

<400>  8

Tyr Arg Gln Trp Ser Phe Arg Gly Arg Thr Phe Trp Ser Cys 
1               5                   10                  


<210>  9
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  hD1 cyclic inhibitory peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  preferably is a D amino acid

<220>
<221>  THIOETH
<222>  (13)..(13)
<223>  Thioether formed with N-chloroacetyl-amino acid in pos. 1

<400>  9

Tyr Ala Ile Ser Tyr Arg Gly Lys Thr Thr Leu Leu Cys 
1               5                   10              


<210>  10
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  hL1 cyclic inhibitory peptide


<220>
<221>  THIOETH
<222>  (17)..(17)
<223>  Thioether formed with N-chloroacetyl-amino acid in pos. 1

<400>  10

Tyr Thr Leu Asn Phe Arg Phe Trp Ser Asp His Ile Ser Trp Tyr Ser 
1               5                   10                  15      


Cys 
    


<210>  11
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  hD2 cyclic inhibitory peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  preferably is a D amino acid

<220>
<221>  THIOETH
<222>  (14)..(14)
<223>  Thioether formed with N-chloroacetyl-amino acid in pos. 1

<400>  11

Tyr His Gln Trp Ser Tyr Arg Gly Ala Thr Tyr Arg Ser Cys 
1               5                   10                  


<210>  12
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  hD3 cyclic inhibitory peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  preferably is a D amino acid

<220>
<221>  THIOETH
<222>  (16)..(16)
<223>  Thioether formed with N-chloroacetyl-amino acid in pos. 1

<400>  12

Tyr Asn Gly Pro Ser Tyr Tyr Arg Leu Arg Ser Trp Leu Ser Ser Cys 
1               5                   10                  15      


<210>  13
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  hD4  inhibitory peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  preferably is a D amino acid

<220>
<221>  THIOETH
<222>  (15)..(15)
<223>  Thioether formed with N-chloroacetyl-amino acid in pos. 1

<400>  13

Tyr Trp Ile Thr His Ser Tyr Arg Gly Leu Ser Lys Ser Phe Cys 
1               5                   10                  15  


<210>  14
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  hD5 inhibitory peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  preferably is a D amino acid

<220>
<221>  THIOETH
<222>  (14)..(14)
<223>  Thioether formed with N-chloroacetyl-amino acid in pos. 1

<400>  14

Tyr Gln Thr Trp Ser Trp Arg Gly Arg Arg Tyr Ser Phe Cys 
1               5                   10                  


<210>  15
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  yL1 icyclic nhibitory peptide


<220>
<221>  THIOETH
<222>  (17)..(17)
<223>  Thioether formed with N-chloroacetyl-amino acid in pos. 1

<400>  15

Tyr Leu His Asp Ser Ala Phe Ser Phe Gly Trp Ser Leu Arg Leu Tyr 
1               5                   10                  15      


Cys 
    


<210>  16
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  yD1 cyclic inhibitory peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  preferably is a D amino acid

<220>
<221>  THIOETH
<222>  (14)..(14)
<223>  Thioether formed with N-chloroacetyl-amino acid in pos. 1

<400>  16

Tyr Arg Gln Trp Ser Phe Arg Gly Arg Thr Phe Trp Ser Cys 
1               5                   10                  


